Perioperative blood glucose metabolism
Conditions
Interventions
Gold Standard:simultaneous POCT papillary blood glucose
to 
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients who are admitted in to the department of pancreatic surgery in Huashan Hospital, and are planned to received selective or confine pancreatic surgery in which there will be a loss of normal pancreas volume. Patients should have no contraindications of planned surgery; 2. Patients aged 18 to 75 years male or female; 3. Patients should have no previous history of any types of diabetes mellitus (except for gestational diabetes mellitus), and should currently not have any medicine for controlling blood glucose; 4. Patients should fully understand the purpose of the study and be willing to participate in this study. All patients should signed the informed consent file before being enrolled in.
Exclusion criteria
Exclusion criteria: 1. Patients who have a local lesion (infection, bruise, etc.) of the skin or subcutaneous tissue at the upper part of their arm, which is not suitable for implanting the FL-FGM sensor; 2. Patients who have a history of anaphylactic reaction to the implanted device; 3. Preoperative lab results showed patients' fasting blood glucose >6.0mmol/L or HbA1c >6.5%; 4. Patients who do not have a complete self-care ability, or are unconsciousness, or cannot cooperative with routine POCT blood glucose metabolism; 5. Patients who are suspected for insulinoma, glucagonoma, ectopic ACTH syndrome or other diseases might have an influence on normal glucose metabolism; 6. Patients who have a previous history of pancreatic surgery or other surgeries which need cardiac bypass or extracorporeal circulation; 7. Patients who are currently having anti-platelet or anti-coagulation drugs (aspirin, warfarin, clopidogrel, etc.), and haven't stop taking the medicine for 2 weeks; 8. Patients who need long term use of glucocorticoids or immunosuppresive drugs; 9. Patients who have moderate to severe comorbidities, or preoperative studies find following results: 9.1 Cardiac function NYHA III-IV, or have a history of acute myocardial infarction in past 6 month. 9.2 Patients who have a history of CODP or asthma, and need long term therapy with oral or inhaled medicine; 9.3 Hepatic function Child-Pugh B-C, or ALT, AST higher than 3 times of the normal upper limit, or TBIL >=100umol/L; 9.4 CKD Stage 4-5, or serum creatinine higher than the normal upper limit. 9.5 Coagulation abnormalities. PT, APTT higher than 1.5 times of the normal upper limit, or INR higher than the normal upper limit, or platelet count =III; 9.9 History stroke in past 6 months; 9.10 Patients comorbid with infectious which have not been controlled yet; 9.11 Patients comorbid with psychological diseases; 10. Patients who have a history of scar constitution; 11. Patients who are pregnant or are in lactation; 12. Patients who have participated in another clinical trail for other drugs or medical equipment; 13. Other circumstance that researchers considering not suitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The accuracy of FL-FGM; | — |
Secondary
| Measure | Time frame |
|---|---|
| The safety of FL-FGM;The pattern of perioperative blood glucose metabolism; | — |
Countries
China
Contacts
Public ContactJi Li
Huashan Hospital, Fudan University
Outcome results
None listed